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4.001
he spread of hypervirulent Clostridium difﬁcile PCR
ibotype 027 in Europe
.J. Kuijper1,∗, D.L. Monnet2
National Reference Laboratory for Clostridium difﬁcile,
eiden, Netherlands
European Centre for Disease Prevention and Control
ECDC), Stockholm, Sweden
ackground: Since 2002, increasing rates of Clostridium
ifﬁcile-associated infections (CDI) with a more severe
ourse, higher mortality and more complications have been
eported in Canada, USA and Europe. This increased viru-
ence is assumed to be associated with higher amounts of
oxin production by a strain belonging to PCR ribotype 027,
oxinotype III (Type 027).
Methods: Following the ﬁrst cases of C. difﬁcile Type
27 in Europe, a network of microbiologists and epidemi-
logists from national reference centers was established.
lostridium difﬁcile strains were sent to National Reference
aboratories for further investigations. The Reference labo-
atory in Leiden conﬁrmed most of the ﬁrst isolated Type
27 isolates in each country.
Results: As of April 2008, C. difﬁcile Type 027 was found
n 16 European member states and in Switzerland. Seven
ountries only reported sporadic cases of Type 027. Of these
countries, 2 countries reported on patients with infec-
ions acquired abroad in countries known to be affected
y Type 027. One country reported an outbreak with the
ndex patient having acquired PCR ribotype 027 during
tay in a foreign hospital. England and Wales, Belgium,
rance, Luxembourg, Finland and The Netherlands reported
high number of hospitals affected by Type 027. Applica-
ion of a recently developed Multi-Locus Variable Number
f Tandem Repeat Analysis (MLVA) for C. difﬁcile on iso-
ates from individual countries revealed speciﬁc subtypes
n some countries. Type 027 isolates were generally suscep-
ible to clindamycin and resistant to erythromycin, however
lindamycin-resistant, erythromycin-resistant, ErmB posi-
ive Type 027 strains have been found in Switzerland,
rance and Ireland. In contrast, erythromycin-susceptible,
lindamycin-susceptible strains were found in Denmark and
ermany. Information on the attributable mortality was
vailable from France (4%)and The Netherlands (4.1%). Sys-
ematic surveillance studies have been developed in all
ountries affected by Type 027, but they differ considerably
n design.Conclusions: C. difﬁcile PCR ribotype 027, toxinotype III
as been found in more than 250 hospitals in 17 countries
nd is rapidly spreading in Europe.
oi:10.1016/j.ijid.2008.05.098
i
t
•
•l Congress on Infectious Diseases Abstracts (Invited Papers)
4.002
iagnosing Clostridium difﬁcile-Associated Diseases: The
tate of the Art
.E. Nord
Karolinska Institute, Stockholm, Sweden
lostridium difﬁcile can cause antibiotic-associated diar-
hea, colitis and pseudomembranous colitis, known as C.
ifﬁcile-associated diseases (CDAD). It has been reported
n the literature since the late 1970s, and outbreaks con-
inue to occur despite breakthroughs in laboratory diagnosis,
ffective treatments and infection control programs. Dur-
ng recent years the number of outbreaks of CDAD that are
evere has risen signiﬁcantly in many North American and
uropean hospitals.
Three virulence factors have been described in C. difﬁ-
ile strains: toxin A (TcdA), toxin B (TcdB) and binary toxin
CDT). Toxin A is a 308-kDa enterotoxin, toxin B is a 270-kDa
ytotoxin and binary toxin is an actin-speciﬁc ADP-ribosyl
ransferase. Toxin A and toxin B are encoded on the large
hromosomal region PaLoc that encompassed the two toxin
enes (tcdA and tcdB) and three additional genes for reg-
latory and transport functions (tcdC, tcdD and tcdE). The
inary toxin is encoded by the cdtA gene (enzymic compo-
ent) and the cdtB gene (binding component). These factors
re now identiﬁed by molecular methods.
The main laboratory diagnostic procedures for CDAD
nvolve cultivation of stool specimens on selective media
nd detection of toxin production by cell culture assays.
everal alternative tests are now available for diagnosis of
DAD, such as latex agglutination, immunoblotting, enzyme
mmunoassay and PCR. The introduction of typing meth-
ds such as PCR, ribotyping and PFGE to follow outbreaks
f CDAD in hospitals and communities has given important
pidemiological data. Real-time PCR to detect tcdA and
cdB genes directly from stool specimens is now available.
he emergence and spread of hypervirulent strains such as
I/NAP1/027 C. difﬁcile has made it mandatory to improve
apid laboratory diagnosis and investigate antibiotic resis-
ance mechanisms.
oi:10.1016/j.ijid.2008.05.099
4.003
reventing New and Recurrent CDAD
. Bartlett
Johns Hopkins University, Baltimore, MD, USA
here are three major risk factors: Advanced age, hospital-
zation or residence in a chronic care facility and exposure
o an antibacterial agent. Principles of prevention:
Antibiotic exposure:Low risk: Urinary antiseptics, sulfonamides, vancomycin,
metronidazole, tetracyclines, narrow spectrum betalac-
tams, macrolides, linezolid, ketolides, TMP-SMX
‘‘Big 3’’: Broad spectrum cephalosporins, ﬂuoro-
quinolones and clindamycin
(Inv
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Infection control: 1) Single room or cohort, 2) bar-
rier precautions, 3) avoid rectal thermometers, 4) chlorine
1000 ppm room cleaning, 5) early detection, 6) BioQuell -
experimental and 7) outbreak - control antibiotics and soap
for hand hygiene.
Prevention of relapses: Avoid ‘‘bad’’ Abx and antiperi-
staltics; role of probiotics and gastric pH control - unknown.
doi:10.1016/j.ijid.2008.05.100
34.004
Managing CDAD: Current and Upcoming Approaches
J. Pepin
U of Sherbrooke, Sherbrooke, Canada
The epidemiology, clinical severity and case-fatality ratio
of Clostridium difﬁcile infection (CDI) changed dramati-
cally with the emergence of a toxin hyperproducing strain
(BI/NAP1/027) in North America and Europe since 2000.
These changes have stimulated the quest for novel thera-
peutic approaches, and a re-examination of the comparative
efﬁcacy of metronidazole versus oral vancomycin. Unfortu-
nately, tolevamer, the only novel treatment evaluated so
far in phase 3 trials, has proven inferior to comparators,
and metronidazole and vancomycin remain the two most
commonly used drugs. The major advantage of metron-
idazole is its low price. The major advantage of orally
administered vancomycin lies in its more favorable phar-
macokinetics. Facilitating vancomycin-resistant enterococci
colonization/infection is a potential drawback of both drugs.
The randomized controlled trials published so far used
intermediate outcomes rather than outcomes that now
preoccupy clinicians: the frequency of complications or
recurrences. Pending the development of a prospectively
validated scoring system, the IDSA/SHEA expert committee
will deﬁne severe CDI as any patient with a leukocyto-
sis ≥15000/mm3 or a creatinine increased by ≥50% from
baseline. For patients with mild-to moderate CDI (leuko-
cytosis <15000/mm3 and creatinine <1.5 X baseline), there
is no evidence that vancomycin is superior to metronida-
zole (even for intermediate outcomes), and metronidazole
should be preferred. For patients with severe CDI not
infected with BI/NAP1/027, there is reasonable evidence
that the better pharmacokinetics of vancomycin translate
into a lower probability of complications. For those infected
with BI/NAP1/027, the superiority of vancomycin remains to
be proven. About one fourth of patients treated with either
metronidazole or vancomycin will experience at least one
recurrence. There is now some evidence that the more com-
mon post-metronidazole recurrences documented recently
in some centers may have corresponded to re-infections
among patients who remained exposed in the hospital envi-
ronment.
doi:10.1016/j.ijid.2008.05.101
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ervical Cancer Vaccination: The Need for Strong and
ustained Protection (invited)
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PV Types 16, 18, 45 and 31: The Most Important
ncogenic HPV Types Worldwide
.X. Bosch
Catalan Institute of Oncology IDIBELL, Barcelona, Spain
PV infections are the most common sexually transmitted
nfections. HPV types differ in transmission capacity, vir-
lence and in their ability to induce cancer. Over 90% of
PV-attributable cancers in women are cervical cancer. Most
ancers of the uterine cervix are squamous cell carcinomas,
hile adenocarcinoma represents 10-12% of the global cer-
ical cancer burden (in some countries of Europe and North
merica it amounts to over 20% of all invasive cervical can-
er).
On worldwide estimates, HPV-16 is consistently the most
ommon type (60%) in cervical cancer, followed by HPV-
8, -45 and -31. These four types combined account for
pproximately 80% of squamous cell carcinomas and 90% of
denocarcinomas. Some variability in the ranking thereafter
as been described.
Infections with HPV-16, -18, or -45 are associated with a
igher risk for progression to cancer. The prognosis of HPV-16
nd -18 is now being established by cohort studies with 10+
ears of follow-up. The probability and time to progression
o HSIL among HPV-16 and/or HPV-18 positive women with
ormal cytology is signiﬁcantly higher than for any other
f the high-risk HPV types, although the estimates for each
ndividual type other than HPV-16 and -18 have not been
rmly established.
Adenocarcinoma is not detected effectively by cervical
creening and is increasing in incidence in Europe and North
merica. It is associated with higher recurrence rates and
oor outcomes. HPV-18 and -45 account for more than 40%
f adenocarcinomas.
Among other HPV positive cancer cases, HPV-16 is the
ominant type. HPV-18 and-45 are the next most common
ypes, although the relative role of the remaining HPV types
s still to be determined.
In summary, on a worldwide scale, prevention of cervi-
al and other genital cancers would greatly beneﬁt from
accination focused on HPV-16 and -18.
oi:10.1016/j.ijid.2008.05.102
5.002
he Value of New Adjuvant Technology
. Zepp1,∗, N. Garc¸on2,∗
Children’s Hospital, Johannes Gutenberg, Mainz, Germany
GSK, Rixensart, Belgium
he development of safe and efﬁcacious vaccines against
athogens like malaria, HIV and TB and the induction of
rotective immune responses in populations with impaired
mmunity such as the elderly remain major challenges. The
rowing understanding of the role of the innate immune sys-
em in the initial triggering of speciﬁc, adaptive immune
